About CAMP4 Therapeutics Corp
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.camp4tx.com/
Frequently Asked Questions
What is the 52-week range for CAMP?
The 52-week high is $7.75 and the 52-week low is $2.8502.
What is the P/E ratio for CAMP?
The P/E ratio data is currently unavailable.
What is the dividend yield for CAMP?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -194.74%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -7.27%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 6.67.
Analyst Recommendation Trends
Wall Street analyst consensus for CAMP over the last few months:
Latest CAMP News
Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6
Chardan Capital analyst Keay Nakae maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Buy and lowers the price target from $6.5 to $6.
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day September 28, 2026 12:00 PM EDTCompany ParticipantsJoshua Mandel-Brehm - CEO, President &...
CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
CAMP4 Therapeutics (NASDAQ:CAMP) said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results targeted for the first half of 2028. The company’s analyst event focused on CMP-002, an antisense oligon
Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day - Slideshow
2026-09-28. The following slide deck was published by Camp4 Therapeutics Corporation in conjunction with this event.
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina Company anticipates initiation of the clinical trial in 4Q 2026 WATERTOWN, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics design
CAMP4 Therapeutics Receives MHRA Authorization To Include UK Sites In Global Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic Candidate For Patients With SYNGAP1-Related Disorder
Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and ArgentinaCompany anticipates
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, will host a virtual Analyst Day on Monday, September 28, 2026 from 12:00 – 1:30 PM ET featuring presentations and Q&A led by CAMP4’s executive leadersh
CAMP4 Therapeutics To Host Virtual Analyst Day To Demonstrate CMP-002 Data To Treat SYNGAP1-Related Disorder
CAMP4 Therapeutics Corporation ("CAMP4") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-31 | Gold Kelly | +10,000 | $3.96 | $39,600 |
| 2026-08-27 | Schwab Andrew J. | -400,000 | $4.04 | $1,616,000 |
| 2026-08-24 | Schwab Andrew J. | -10 | $4.5 | $45 |
| 2026-08-21 | Schwab Andrew J. | -32,018 | $4.5 | $144,081 |
| 2026-08-20 | Schwab Andrew J. | -114,700 | $4.54 | $520,738 |
| 2026-08-19 | Tardiff Daniel | -1,738 | $4.76 | $8,273 |
| 2026-08-19 | Schwab Andrew J. | -45,147 | $4.76 | $214,900 |
| 2026-08-03 | Maricich Yuri | +6,551 | $1.65 | $10,809 |
| 2026-08-03 | Gold Kelly | +6,551 | $1.65 | $10,809 |
| 2026-08-03 | Mandel-Brehm Josh | +6,551 | $1.65 | $10,809 |
| 2026-08-03 | 5AM Partners VI, LLC | +3,179,558 | $1.5299 | $4,864,406 |
| 2026-08-03 | Schwab Andrew J. | +3,179,558 | $1.5299 | $4,864,406 |
| 2026-08-03 | Young Richard A | +16,378 | $1.65 | $27,024 |
| 2026-06-10 | Stewart Murray | +28,000 | - | - |
| 2026-06-10 | Schwab Andrew J. | +28,000 | - | - |
| 2026-06-10 | Nashat Amir | +28,000 | - | - |
| 2026-06-10 | Young Richard A | +28,000 | - | - |
| 2026-06-10 | Holtzman Steven H | +28,000 | - | - |
| 2026-06-10 | WILLIAMS DOUGLAS E | +28,000 | - | - |
| 2026-04-01 | Tardiff Daniel | +170,000 | - | - |
| 2026-04-01 | Gold Kelly | +215,000 | - | - |
| 2026-04-01 | Mandel-Brehm Josh | +580,000 | - | - |
| 2026-04-01 | Maricich Yuri | +215,000 | - | - |
| 2026-04-01 | MacLean Michael F | +56,000 | - | - |
| 2025-12-11 | Tardiff Daniel | +145,500 | - | - |
| 2025-12-11 | Gold Kelly | +190,000 | - | - |
| 2025-12-11 | Mandel-Brehm Josh | +425,000 | - | - |
| 2025-12-11 | Maricich Yuri | +190,000 | - | - |